产品详情
| 中文名称:阿贝西利 | 英文名称:Abemaciclib |
| CAS:1231929-97-7 | 纯度规格: 99%+ HPLC |
| 产品类别: 医药原料药 |
2025-11-27
阿贝西利
Abemaciclib
5KG/RMB;25KG/RMB;100KG/RMB
99%+ HPLC
医药原料药
通用名(中文):阿贝西利
通用名(英文):Abemaciclib
CAS No.:1231929-97-7
分子式:C27H32F2N8
分子量:506.59
外 观:白色至黄色粉末。
用途:用于治疗激素受体阳性且HER2阴性的早期乳腺癌、晚期或转移性乳腺癌(国内进口原研)。
阿贝西利(abemaciclib)是美国礼来公司研发的一种口服有效的细胞周期蛋白依赖性激酶(cyclin-dependent kinases,CDKs)抑制剂,靶向作用于CDK4(cyclin D1)和CDK6(cyclin D3)细胞周期通路,具有较好的抗肿瘤活性。该药于2017年9月28日经美国FDA批准上市。
关键字: 1231929-97-7;阿贝西利;Abemaciclib;海步医药;
公司简介
Beijing Hope Pharmaceutical Co., Ltd., established in 2005, is a high-tech enterprise with "chemical drug technology development-Process Optimization-Regulation registration and approval" as its core competence, and has won the title of "China Top 20 Pharmaceutical R&D Company" for several times. Hope Pharma actively builds one-stop service for drug CRO and CDMO, continuously expands its service areas, and establishes good cooperative relations with some leading pharmaceutical companies domestic and abroad.
Hope Pharma has over 20 years of experience in project evaluation, innovation-oriented patent around design, pre-clinical development, clinical trial practice, registration, marker authorization, etc..Our products involve anti-tumor, anti-depressant, anti-epileptic, anxiolytic, cardiovascular and cerebrovascular, digestive system, respiratory system and other indications.
Until now, more than 140 technology transform, over 90 registration approvals and 73 patents has been finished in Hope(including subsidiaries) for past 20 years, and has been rated as a national high-tech enterprise.
| 成立日期 |
2005-04-26
(21年)
|
注册资本 |
4284.6849 万元人民币
|
| 员工人数 |
100-500人 |
年营业额 |
¥ 1亿以上 |
| 主营行业 |
医药中间体,医药中间体,原料药,原料药 |
经营模式 |
工厂,定制,工厂,定制 |